Ovulation News and Research

RSS

Ovulation is the process in a female's menstrual cycle by which a mature ovarian follicle ruptures and discharges an ovum (also known as an oocyte, female gamete, or casually, an egg). Ovulation also occurs in the estrous cycle of other female mammals, which differs in many fundamental ways from the menstrual cycle. The time immediately surrounding ovulation is referred to as the ovulatory phase or the periovulatory period.

Fertility drugs cause a high percentage of multiple births; contribute to growing crisis of prematurity

The widespread use of so-called fertility drugs, not just high-tech laboratory procedures, likely plays a larger role than previously realized in the growing problem of premature births in the United States, because these drugs cause a high percentage of multiple births, the March of Dimes said today.

18 Jan 2010

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

Antares Pharma, Inc. and the Population Council today announced successful results from a dose-finding Phase 2 trial for a novel contraceptive gel containing the progestin Nestorone and estradiol (NES/E2) utilizing the Antares ATD (advanced transdermal delivery) gel system. Based on this successful data, the two parties continue to expect to partner with a worldwide or regional pharmaceutical company in order to commercialize this novel contraceptive gel.

12 Jan 2010

Ovu-Trac kit for successful family planning

A recent British study revealed that over a third of the female test subjects could not recognize their own signs of fertility. Accurately identifying the signs of ovulation and how they relate to a woman's fertile phase is the key to successful family planning. However, just like anything else, it takes time to learn.

10 Dec 2009

New article in Women's Health journal emphasizes the importance of early pregnancy detection

A new article published in the peer-reviewed journal Women's Health emphasizes the importance of early pregnancy detection. Using research conducted on behalf of Church & Dwight Co. Inc., the makers of First Response, the article reviews data that shows not all at-home pregnancy tests are created equal -First Response brand pregnancy tests are more sensitive and able to detect key variants of the pregnancy hormone better than other at home pregnancy tests.

9 Dec 2009

China life science companies receive 'Most Promising Company' awards

The 7th ChinaBio® Investor Forum, held December 2-3, 2009 in Tianjin, concluded a successful meeting by giving “Most Promising Company” awards to two young China life science companies.

7 Dec 2009

CRINONE vaginal progesterone gel as effective as IM progesterone for luteal phase support in IVF-ET

In their American Society of Reproductive Medicine (ASRM) conference wrap-up, Medscape highlighted the article published by them on October 27, 2009, which summarized the results from the largest prospective, randomized clinical study to compare vaginal progesterone to intramuscular progesterone injections (IM progesterone) for luteal support in infertility treatment.

9 Nov 2009

Scientific and medical community mourns the loss of Emeritus Professor James Boyer Brown

The scientific and medical community mourns the loss of our esteemed colleague and good friend Emeritus Professor James Boyer Brown AM, MSc (NZ), PhD (Edin), MSc (Melb), DSc (Edin), FRANZCOG (Ad Eundem), Life Member Fertility Society of Australia, Life Member Endocrine Society of Australia, who passed away on Saturday 31st October 2009, aged 90.

4 Nov 2009

New advanced fertility monitor for women

1 in 6 British couples now face problems conceiving, so maximising the chances of natural conception by identifying precisely when ovulation occurs is critical.

4 Nov 2009

Male attraction operates differently from female attraction, regardless of sexual orientation

A new study from a researcher at Harvard University finds that gay men are most attracted to the most masculine-faced men, while straight men prefer the most feminine-faced women.

31 Oct 2009

Study shows 62.2 percent of women turn to alternative therapies before medical treatments for infertility

In a recent study from the Ohio State University Medical Center, 62.2 percent of those surveyed turned to alternative therapies before turning to more invasive medical treatments for infertility and getting pregnant.

29 Oct 2009

Combination treatement for IVF patients may eliminate vaginal bleeding

A prospective, multi-center study demonstrated that in IVF (in vitro fertilization) cycles supplemented with once-daily dosing of Crinone® vaginal progesterone gel and Estrace® oral estrogen, vaginal bleeding is rare in patients who become pregnant. Bleeding does occur in approximately one-quarter of patients who do not become pregnant. These data were presented at the American Society for Reproductive Medicine (ASRM) annual meeting in Atlanta.

23 Oct 2009

No significant differences in pregnancy outcomes with different progesterone formulations

A retrospective analysis, conducted at a large infertility clinic between January 2003 and December 2008, demonstrated that there were no significant differences in pregnancy outcomes with three different progesterone formulations for women aged 35 to 40 undergoing in vitro fertilization-embryo transfer (IVF-ET) procedures. These data were presented at the American Society for Reproductive Medicine (ASRM) annual meeting in Atlanta.

21 Oct 2009

DuoFertility helps women to conceive naturally without IVF

One in six women in the UK have difficulties conceiving – a figure which is predicted to rise to one in three by 2020. Many women turn to costly, invasive fertility treatments such as IVF, which typically has a success rate of 20%. DuoFertility is a groundbreaking new fertility monitor which helps women to maximise their chances of conceiving naturally without resorting to fertility treatment.

9 Oct 2009

Birth control pills may have an impact on choice of partners

There is no doubt that modern contraception has enabled women to have unprecedented control over their own fertility. However, is it possible that the use of oral contraceptives is interfering with a woman's ability to choose, compete for and retain her preferred mate?

8 Oct 2009

Role of gene that could influence fertility identified in mice

Virginia Commonwealth University researchers have identified the role of a gene in regulating molecular signals involved with ovarian follicle development, which may one day help shed light on some of the causes of fertility issues in humans.

3 Oct 2009

Æterna Zentaris announces results of its cetrorelix pamoate clinical development program TQT trial

Æterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that the 043 Thorough QT (TQT) trial, which is part of the cetrorelix pamoate clinical development program in benign prostatic hyperplasia (BPH), met its primary endpoint.

30 Sep 2009

Drugs industry names the contraceptive pill as the greatest pharmacy innovation of the past 150 years

The Contraceptive Pill has been crowned the greatest pharmacy innovation of the past 150 years, by leading figures in the drugs industry.

18 Sep 2009

Contraceptive pill likely cause for 20 percent drop in ovarian cancer rates

Ovarian cancer rates have fallen by almost 20 per cent in a decade, according to Cancer Research UK today (Wednesday).

8 Sep 2009

Study on basic mechanisms that control fertility in worms may help to know how some woman regain their fertility after cancer treatment

Scientific dogma has long asserted that females are born with their entire lifetime's supply of eggs, and once they're gone, they're gone. New findings by researchers at Fred Hutchinson Cancer Research Center, published online Aug. 27 in Science, suggest that in nematode worms, at least, this does not hold true.

28 Aug 2009

Aeterna Zentaris announces results from trials of Cetrorelix in benign prostatic hyperplasia

AEterna Zentaris Inc. today reported Phase 3 results for its North American efficacy trial Z-033 and the safety trial Z-041 in benign prostatic hyperplasia (BPH), with its lead endocrinology compound for urology, cetrorelix pamoate. As announced on March 6, 2009, sanofi-aventis U.S. LLC entered into an agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

17 Aug 2009